News & Media Press releases & statements Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Year All Years 2023 2022 2021 2020 2019 2018 2017 2016 2015 Category All categories Type - Statement - Press release Topic - Corporate and finance - Global health - Partnerships Research area - COVID-19 - Ebola - RSV - Seasonal influenza Uncategorized Keywords Apply filter Advanced Search Search Search Headlines Only Type All Statement Press release Topic All Corporate and finance Global health Partnerships Research area All COVID-19 Ebola RSV Seasonal influenza From To Asset Types Photos Video Audio Documents Events Standard Aug 22, 2022 StatementCOVID-19 U.S. Centers for Disease Control and Prevention Expands Recommendation for Novavax COVID-19 Vaccine, Adjuvanted to Adolescents Aged 12 Through 17 Download Aug 10, 2022 StatementCOVID-19 Novavax and Serum Institute of India Receive Expanded Emergency Use Authorization for Novavax’ COVID-19 Vaccine in Thailand in Adolescents Aged 12 Through 17 Download Aug 8, 2022 StatementCorporate and finance Novavax Statement on Second Quarter 2022 Financial Results and Operational Highlights Download Aug 1, 2022 StatementCOVID-19 Novavax Statement on U.S. Vaccinations with the Novavax COVID-19 Vaccine, Adjuvanted Underway Download Jul 28, 2022 StatementCorporate and finance Novavax CEO Appointed to U.S.-India CEO Forum Download Jul 22, 2022 StatementCOVID-19 Novavax Statement on U.S. Availability of the Novavax COVID-19 Vaccine, Adjuvanted Download Jul 19, 2022 StatementCOVID-19 U.S. Centers for Disease Control and Prevention Endorses Advisory Committee on Immunization Practices’ Recommendation for Novavax COVID-19 Vaccine, Adjuvanted Download Jul 15, 2022 StatementCOVID-19 Novavax COVID-19 Vaccine to be Reviewed at U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices Meeting on July 19, 2022 Download Jul 14, 2022 StatementCOVID-19 Novavax Statement on European Medicines Agency Nuvaxovid™ Label Update Related to Allergic Reaction Download Jul 7, 2022 StatementGlobal healthCOVID-19 Novavax Files in Switzerland for Expanded Conditional Marketing Authorization of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Individuals Aged 18 and Over Download Show 5102550100 per page«123456»